AR066412A1 - Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad. - Google Patents
Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.Info
- Publication number
- AR066412A1 AR066412A1 ARP080101855A ARP080101855A AR066412A1 AR 066412 A1 AR066412 A1 AR 066412A1 AR P080101855 A ARP080101855 A AR P080101855A AR P080101855 A ARP080101855 A AR P080101855A AR 066412 A1 AR066412 A1 AR 066412A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- alkynyl
- haloalkyl
- cycloalkyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical class C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000012010 growth Effects 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 27
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000000304 alkynyl group Chemical group 0.000 abstract 11
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 abstract 10
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 9
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001336 alkenes Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92756307P | 2007-05-04 | 2007-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066412A1 true AR066412A1 (es) | 2009-08-19 |
Family
ID=39944224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101855A AR066412A1 (es) | 2007-05-04 | 2008-04-30 | Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100227859A1 (enExample) |
| EP (1) | EP2144893A2 (enExample) |
| JP (1) | JP2010526106A (enExample) |
| AR (1) | AR066412A1 (enExample) |
| CA (1) | CA2685389A1 (enExample) |
| CL (1) | CL2008001257A1 (enExample) |
| MX (1) | MX2009011749A (enExample) |
| PA (1) | PA8779101A1 (enExample) |
| PE (1) | PE20090223A1 (enExample) |
| TW (1) | TW200900397A (enExample) |
| WO (1) | WO2008137816A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008137583A (ru) * | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейшн (Us) | Спиропиперидины в качестве модуляторов мускариновых рецепторов |
| WO2010091185A2 (en) * | 2009-02-05 | 2010-08-12 | Trustees Of Boston College | Inhibitors of fructose 1,6-bisphosphatase and methods of use thereof |
| SG175048A1 (en) * | 2009-04-06 | 2011-11-28 | Schering Corp | Indole derivatives and methods for antiviral treatment |
| CN104995559B (zh) | 2013-02-08 | 2020-04-07 | 三菱瓦斯化学株式会社 | 抗蚀剂组合物、抗蚀图案形成方法和用于其的多元酚衍生物 |
| EP2970312B1 (en) * | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| EP2907512A1 (en) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibitors of MMP-12 as antiviral Agents |
| WO2016104214A1 (ja) | 2014-12-25 | 2016-06-30 | 三菱瓦斯化学株式会社 | 化合物、樹脂、リソグラフィー用下層膜形成材料、リソグラフィー用下層膜、パターン形成方法及び精製方法 |
| EP3279190B1 (en) | 2015-03-31 | 2020-08-12 | Mitsubishi Gas Chemical Company, Inc. | Resist composition, method for forming resist pattern, and polyphenol compound used therein |
| CN107533291B (zh) * | 2015-03-31 | 2021-06-11 | 三菱瓦斯化学株式会社 | 化合物、抗蚀剂组合物及使用其的抗蚀图案形成方法 |
| JP6919838B2 (ja) | 2015-08-31 | 2021-08-18 | 三菱瓦斯化学株式会社 | リソグラフィー用下層膜形成材料、リソグラフィー用下層膜形成用組成物、リソグラフィー用下層膜及びその製造方法、パターン形成方法、樹脂、並びに精製方法 |
| CN107924131B (zh) | 2015-08-31 | 2020-12-25 | 三菱瓦斯化学株式会社 | 光刻用下层膜形成材料及其组合物用于形成光刻用下层膜的用途、以及抗蚀图案形成方法 |
| KR102687507B1 (ko) | 2015-09-10 | 2024-07-24 | 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 | 화합물, 수지, 레지스트 조성물 또는 감방사선성 조성물, 레지스트 패턴 형성방법, 아몰퍼스막의 제조방법, 리소그래피용 하층막 형성재료, 리소그래피용 하층막 형성용 조성물, 회로패턴의 형성방법 및 정제방법 |
| US10042251B2 (en) | 2016-09-30 | 2018-08-07 | Rohm And Haas Electronic Materials Llc | Zwitterionic photo-destroyable quenchers |
| GB201617339D0 (en) | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| KR102435507B1 (ko) * | 2019-07-31 | 2022-08-24 | 일동제약(주) | 신규 벤조퓨란 유도체 및 이의 용도 |
| KR20230012474A (ko) | 2020-05-15 | 2023-01-26 | 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 | 화합물, (공)중합체, 조성물, 레지스트패턴 형성방법, 그리고 화합물 및 (공)중합체의 제조방법 |
| CN113929645B (zh) * | 2021-12-15 | 2022-03-11 | 长沙普济生物科技股份有限公司 | 一种光催化合成苯并呋喃基氨基酸表面活性剂的方法 |
| CN117045635A (zh) * | 2022-05-13 | 2023-11-14 | 中国海洋大学 | 一种3-苯基二苯并呋喃类化合物在药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ333063A (en) * | 1996-09-04 | 2000-12-22 | Warner Lambert Co | Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors |
| KR20000068415A (ko) * | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법 |
| TR200202211T2 (tr) * | 1999-08-18 | 2002-11-21 | Warner-Lambert Company | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri |
| MXPA01013172A (es) * | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US20030157110A1 (en) * | 2002-01-07 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
| EP2074107A2 (en) * | 2006-10-27 | 2009-07-01 | Wyeth a Corporation of the State of Delaware | Tricyclic compounds as matrix metalloproteinase inhibitors |
-
2008
- 2008-04-30 AR ARP080101855A patent/AR066412A1/es unknown
- 2008-04-30 PA PA20088779101A patent/PA8779101A1/es unknown
- 2008-04-30 CL CL200801257A patent/CL2008001257A1/es unknown
- 2008-04-30 PE PE2008000773A patent/PE20090223A1/es not_active Application Discontinuation
- 2008-05-05 MX MX2009011749A patent/MX2009011749A/es not_active Application Discontinuation
- 2008-05-05 CA CA002685389A patent/CA2685389A1/en not_active Abandoned
- 2008-05-05 EP EP08755041A patent/EP2144893A2/en not_active Withdrawn
- 2008-05-05 JP JP2010506709A patent/JP2010526106A/ja not_active Withdrawn
- 2008-05-05 US US12/598,868 patent/US20100227859A1/en not_active Abandoned
- 2008-05-05 WO PCT/US2008/062593 patent/WO2008137816A2/en not_active Ceased
- 2008-05-05 TW TW097116522A patent/TW200900397A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100227859A1 (en) | 2010-09-09 |
| JP2010526106A (ja) | 2010-07-29 |
| MX2009011749A (es) | 2009-11-11 |
| WO2008137816A2 (en) | 2008-11-13 |
| CA2685389A1 (en) | 2008-11-13 |
| WO2008137816A3 (en) | 2009-05-14 |
| EP2144893A2 (en) | 2010-01-20 |
| TW200900397A (en) | 2009-01-01 |
| WO2008137816A8 (en) | 2010-01-28 |
| CL2008001257A1 (es) | 2008-07-04 |
| PE20090223A1 (es) | 2009-03-08 |
| PA8779101A1 (es) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100397T1 (hr) | INHIBITORI 11-ß-HIDROKSISTEROID-DEHIDROGENAZE 1 | |
| AR071072A1 (es) | Inhibidores de desacetilasas b a base de hidroxamato | |
| PE20221083A1 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso | |
| CO6241190A2 (es) | Compuestos para inhibicion enzimatica | |
| AR061838A1 (es) | Moduladores de propiedades farmacocineticas de terapeuticos | |
| AR076067A1 (es) | Composiciones y metodos para modular la senda de senalizacion de wnt | |
| AR075731A1 (es) | Derivados heterociclicos de bencimidazoles, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento del virus sincicial respiratorio(vsr). | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| PE20091371A1 (es) | Inhibidores de hsp90 | |
| AR061667A1 (es) | Arilamidas sustituidas con tetrazol | |
| RU2008151690A (ru) | Контролируемое высвобождение фенольных опиатов | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR039672A1 (es) | Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat) | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| PE20130150A1 (es) | Inhibidores de las iap | |
| AR043063A1 (es) | Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas | |
| AR059425A1 (es) | Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1 | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| CO6210811A2 (es) | Inhibidores de aldh-2 en el tratamiento de la adiccion | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| NO20081327L (no) | Kinoliner og terapeutisk anvendelse derav | |
| AR078131A1 (es) | Conjugados su preparacion y su aplicacion terapeutica | |
| CO5180545A1 (es) | Moduladores excitativos receptores de aminoacidos como moduladores excitatorios de receptores de aminoacido | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| ES2634841T3 (es) | Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |